Clinical practice guideline for lympoma in China (2021 Edition).
10.3760/cma.j.cn112152-20210516-00382
- Collective Name:China Anti-cancer Association Lymphoma Committee;Chinese Association for Clinical Oncologists;Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Guideline;
Lymphoma;
Therapy
- MeSH:
China/epidemiology*;
Hodgkin Disease/drug therapy*;
Humans;
Lymphoma/therapy*;
Lymphoma, Non-Hodgkin/drug therapy*;
Medical Oncology
- From:
Chinese Journal of Oncology
2021;43(7):707-735
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoma is one of the most common malignancies in China. In China, there were 6 829 new Hodgkin lymphoma cases and 2 807 deaths in 2020, with 92 834 new non-Hodgkin lymphoma cases and 54 351 deaths. Due to the complicated pathological subtypes and heterogeity, the treatment strategies for lymphoma vary largely. In recent years, with the deep understanding for the nature of lymphoma, much research progress has been achieved in the diagnosis and treatment, leading to a remarkable improvement in survival outcome of patients. In order to update the progress in the treatment of lymphoma worldwide timely, and further improve the level of standardized diagnosis and treatment of lymphoma in China, the China Anti-cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate "Clinical practice guideline for lympoma in China (2021 Edition)" .
